埃索美拉唑四联疗法对消化性溃疡Hp感染患者炎性指标的影响

承德医学院学报 ›› 2020, Vol. 37 ›› Issue (4): 287-289.

埃索美拉唑四联疗法对消化性溃疡Hp感染患者炎性指标的影响

马远红

三门峡市渑池县中医院,河南三门峡 472400

收稿日期:2020-03-10 出版日期:2020-08-10 发布日期:2021-11-19

Effect of Esomeprazole Quadruple Therapy on Inflammatory Indexes of Patients with Peptic Ulcer Hp Infection

MA Yuan-hong

Mianchi Traditional Chinese Medicine Hospital of Sanmenxia City, Henan Sanmenxia 472400, China

Received:2020-03-10 Online:2020-08-10 Published:2021-11-19

摘要/Abstract

摘要： 目的探讨埃索美拉唑四联疗法对消化性溃疡幽门螺杆菌（Hp）感染患者的应用效果。方法回顾性分析2018年1月至2019年1月于我院接受治疗的消化性溃疡Hp感染患者的临床资料,抽取40例接受奥美拉唑四联疗法（奥美拉唑、枸橼酸铋钾、阿莫西林克拉维酸钾片、莫西沙星片）治疗的患者组成对照组,抽取40例经埃索美拉唑四联疗法（埃索美拉唑、枸橼酸铋钾、阿莫西林克拉维酸钾片、莫西沙星片）治疗的患者组成观察组,比较两组肿瘤坏死因子α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）的水平改变及不良反应发生情况。结果观察组TNF-α、IL-6、IL-8水平低于对照组（P<0.05）;观察组治疗后Hp转阴率高于对照组,差异有统计学意义（χ²=4.588,P<0.05）;两组不良反应发生率比较,差异无统计学意义（P>0.05）。结论埃索美拉唑四联疗法可下调消化性溃疡Hp感染患者炎性指标水平,促进Hp转阴,且其不良反应发生较少,安全性较高。

关键词: 消化性溃疡, 幽门螺杆菌感染, 埃索美拉唑四联疗法, 炎性指标

Abstract: Objective To explore the effect of esomeprazole quadruple therapy on patients with peptic ulcer Helicobacter pylori (Hp) infection. Methods The clinical data of patients with peptic ulcer Hp infection who were treated in our hospital from January 2018 to January 2019 were retrospectively analyzed. A total of 40 patients who received omeprazole quadruple therapy (omeprazole, bismuth potassium citrate, amoxicillin clavulanate tablets, moxifloxacin tablets) were selected as the control group, and a total of 40 patients treated with esomeprazole quadruple therapy (esomeprazole, bismuth potassium citrate, amoxicillin clavulanate tablets, moxifloxacin tablets) were selected to form the observation group. Tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8) and the occurrence of adverse reactions were compared. Results TNF-α, IL-6, IL-8 The level of the observation group was statistically lower than that of the control group (P<0.05); The observation group had a higher Hp negative rate than that of the control group after treatment, and the difference was statistically significant (P<0.05); The incidence of adverse reactions between the two groups was not statistically significant (P>0.05). Conclusion Esomeprazole quadruple therapy can reduce the level of inflammatory index in patients with peptic ulcer Hp infection, promote Hp to negative, and it has fewer adverse reactions and higher safety.

Key words: peptic ulcer, helicobacter pylori infection, esomeprazole quadruple therapy, inflammatory indicators

中图分类号:

R573.1

马远红. 埃索美拉唑四联疗法对消化性溃疡Hp感染患者炎性指标的影响[J]. 承德医学院学报, 2020, 37(4): 287-289.

MA Yuan-hong. Effect of Esomeprazole Quadruple Therapy on Inflammatory Indexes of Patients with Peptic Ulcer Hp Infection[J]. Journal of Chengde Medical University, 2020, 37(4): 287-289.

参考文献

[1] 王庆军,柴慈曼. 埃索美拉唑四联疗法治疗幽门螺杆菌感染相关胃溃疡的疗效[J]. 江苏医药,2018,44(8):884-888.
[2] 孙广红. 埃索美拉唑与奥美拉唑四联疗法对消化性溃疡合并幽门螺杆菌感染患者预后及生活质量影响对比研究[J]. 山西医药杂志,2018,47(17):49-51.
[3] 王炳英. 埃索美拉唑、奥美拉唑为主的三联疗法治疗幽门螺杆菌阳性消化性溃疡效果比较[J]. 山东医药,2015,55(38):77-78.
[4] 黄晓东,陈林峰,许特,等. 埃索美拉唑治疗成人活动期胃溃疡51例疗效观察[J]. 海南医学,2018,29(12):26-28.
[5] 朱铢. 不同抑酸剂与抗生素联用治疗消化性溃疡的临床疗效及其对炎性因子的影响[J]. 标记免疫分析与临床,2016,23(7):779-782.
[6] Fashner J,Gitu AC.Diagnosis and Treatment of Peptic Ulcer Disease and H. pylori Infection[J]. American Family Physician,2015,91(4): 236-242.
[7] 孙晓,孙万日. 埃索美拉唑、铝碳酸镁和莫沙比利联合使用在GERD、Hp相关性胃炎中的应用价值[J]. 热带医学杂志,2018,18(4):107-111.
[8] 宋晓华,邵玉霞,娄渊贵,等. 埃索美拉唑镁治疗幽门螺杆菌阳性胃十二指肠炎的临床疗效及安全性[J]. 中国老年学杂志,2017,37(17):4320-4321.
[9] 赖人旭,任江南,苟新敏,等.铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床研究[J]. 中国临床药理学杂志,2017,33(19):1868-1870.
[10] 徐建峰. 埃索美拉唑、克拉霉素、阿莫西林联合治疗幽门螺杆菌阳性胃溃疡患者102例疗效观察[J].中国临床医生杂志,2015,43(5):56-58.
[11] 许静亚. 埃索美拉唑联合抗菌药物治疗幽门螺旋杆菌阳性慢性胃炎的效果[J]. 安徽医学,2016,37(10):1265-1266,1267.
[12] 罗哲,崔立红. 奥美拉唑与埃索美拉唑治疗消化道溃疡的临床疗效分析[J]. 检验医学与临床,2016,13(2):233-235.
[13] 张洁,刘倩,徐鑫,等. 埃索美拉唑对治疗Hp感染十二指肠溃疡患者的血清IL-8与IL-10及胃液表皮生长因子的影响研究[J]. 中华医院感染学杂志,2018,28(16):102-105,109.
[14] 李艳林,程芳,陈凌,等. 以埃索美拉唑、奥美拉唑为主的三联疗法治疗幽门螺杆菌相关性胃溃疡的疗效比较[J]. 中国医院用药评价与分析,2018,18(7):21-22,25.
[15] 伍建业,周莹群,郭传勇,等. 埃索美拉唑、克拉霉素、阿莫西林序贯疗法与三联疗法治疗Hp阳性十二指肠溃疡的疗效及经济学对比[J]. 中国药物警戒,2016,13(10): 581-586.